Peptides DB
Research-centric peptide and protocol reference hub
Study 6 of 14IGF-1 LR3 (Long R3 IGF-1) literaturePubMed2023

Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris.

The study successfully produced high levels of IGF-1 and LR3 IGF-1 in Pichia pastoris, achieving 0.5 g/L and 1 g/L respectively, but does not provide detailed clinical implications.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the igf-1 lr3 (long r3 igf-1) corpus
3
Preclinical · this one
10
Observational
0
Open-label
1
Randomised
0
Reviews

Summary and findings

This study reports the recombinant expression of human IGF-1 and its analog Long R3 IGF-1 (LR3 IGF-1) in the Pichia pastoris expression system. The expression levels reached approximately 0.5 g/L for XynCDBFV-IGF-1 and 1 g/L for XynCDBFV-LR3 IGF-1. The purified proteins displayed bioactivity in cell proliferation assays compared to standard IGF-1.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
0.5 g/L XynCDBFV-IGF-1 and 1 g/L XynCDBFV-LR3 IGF-1 achieved in a 15-L bioreactor.2023

Abstract

The authors’ words, as PubMed supplied them

Insulin-like growth factor-1 (IGF-1) is a pleiotropic protein hormone and has become an attractive therapeutic target because of its multiple roles in various physiological processes, including growth, development, and metabolism. However, its production is hindered by low heterogenous protein expression levels in various expression systems and hard to meet the needs of clinical and scientific research. Here, we report that human IGF-1 and its analog Long R3 IGF-1 (LR3 IGF-1) are recombinant expressed and produced in the Pichia pastoris (P. pastoris) expression system through being fused with highly expressed xylanase XynCDBFV. Furthermore, purified IGF-1 and LR3 IGF-1 display excellent bioactivity of cell proliferation compared to the standard IGF-1. Moreover, higher heterologous expression levels of the fusion proteins XynCDBFV-IGF-1 and XynCDBFV-LR3 IGF-1 are achieved by fermentation in a 15-L bioreactor, reaching up to about 0.5 g/L XynCDBFV-IGF-1 and 1 g/L XynCDBFV-TEV-LR3 IGF-1. Taken together, high recombinant expression of bioactive IGF-1 and LR3 IGF-1 is acquired with the assistance of xylanase as a fusion partner in P. pastoris, which could be used for both clinical and scientific applications. KEY POINTS: • Human IGF-1 and LR3 IGF-1 are produced in the P. pastoris expression system. • Purified IGF-1 and LR3 IGF-1 show bioactivity comparable to the standard IGF-1. • High heterologous expression of IGF-1 and LR3 IGF-1 is achieved by fermentation in a bioreactor.

Background

The paper addresses the production of IGF-1 and its analog LR3 IGF-1, which are important for various biological functions. Prior knowledge indicates that IGF-1 plays a role in growth and development, but efficient production methods are necessary for research and potential applications. This study is significant as it explores a novel expression system using Pichia pastoris.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the IGF-1 LR3 (Long R3 IGF-1) corpus

BLong-anchoring Stent Method as a Rescue Technique for Early Dysfunction of Covered Self-Expandable Metal Stents in Distal Malignant Biliary Obstruction: A Retrospective Case Series.DEN open · 2023 · n=15 · Median angle of the SEMS significantly straightened from 128.3° to 151.5° after anchoring stent placement, p < 0.001.HumanBUlcerative Esophagitis With Marked Eosinophilic Infiltration and Fluorodeoxyglucose-Positron Emission Tomography Positivity Requiring Differentiation From Esophagogastric Junction Carcinoma.DEN open · 2023 · n=1 · 70 eosinophils per high-power field in biopsy specimens.HumanBSuccessful Endoscopic Submucosal Dissection for Primary Esophageal Mucosa-Associated Lymphoid Tissue Lymphoma.DEN open · 2026 · n=1 · Not reported in abstract.HumanABalanced Fluid or 0.9% Saline in Children Treated for Septic Shock.The New England journal of medicine · 2026 · A primary-outcome event occurred in 137 patients (3.4%) in the balanced-fluid group and in 124 (3.0%) in the 0.9%-saline group.HumanDAzacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.The New England journal of medicine · 2026DLong-term effectiveness of typhoid conjugate vaccine in Nepal.The Lancet. Global health · 2026